These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24809089)

  • 1. Idelalisib: targeting PI3Kδ in B-cell malignancies.
    Gilbert JA
    Lancet Oncol; 2014 Mar; 15(3):e108. PubMed ID: 24809089
    [No Abstract]   [Full Text] [Related]  

  • 2. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3Kδ inhibition hits a sensitive spot in B cell malignancies.
    Vanhaesebroeck B; Khwaja A
    Cancer Cell; 2014 Mar; 25(3):269-71. PubMed ID: 24651009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idelalisib--a PI3Kδ inhibitor for B-cell cancers.
    Fruman DA; Cantley LC
    N Engl J Med; 2014 Mar; 370(11):1061-2. PubMed ID: 24620870
    [No Abstract]   [Full Text] [Related]  

  • 5. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
    Burger JA; Okkenhaug K
    Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idelalisib for chronic lymphocytic leukemia.
    Brown JR
    Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
    [No Abstract]   [Full Text] [Related]  

  • 8. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
    Keating GM
    Target Oncol; 2015 Mar; 10(1):141-51. PubMed ID: 25637459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.
    Sujobert P; Rioufol C; Salles GA
    Cancer J; 2016; 22(1):12-6. PubMed ID: 26841011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.
    Hewett YG; Uprety D; Shah BK
    J Oncol Pharm Pract; 2016 Apr; 22(2):284-8. PubMed ID: 25712626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma.
    Okoli TC; Peer CJ; Dunleavy K; Figg WD
    Cancer Biol Ther; 2015; 16(2):204-6. PubMed ID: 25756507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idelalisib, ibrutinib show benefits in CLL.
    Cancer Discov; 2014 Apr; 4(4):382. PubMed ID: 24706642
    [No Abstract]   [Full Text] [Related]  

  • 13. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
    Lampson BL; Brown JR
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.
    Miller BW; Przepiorka D; de Claro RA; Lee K; Nie L; Simpson N; Gudi R; Saber H; Shord S; Bullock J; Marathe D; Mehrotra N; Hsieh LS; Ghosh D; Brown J; Kane RC; Justice R; Kaminskas E; Farrell AT; Pazdur R
    Clin Cancer Res; 2015 Apr; 21(7):1525-9. PubMed ID: 25645861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idelalisib.
    Zirlik K; Veelken H
    Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
    Greenwell IB; Flowers CR; Blum KA; Cohen JB
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idelalisib approved for three blood cancers.
    Traynor K
    Am J Health Syst Pharm; 2014 Sep; 71(17):1430. PubMed ID: 25147161
    [No Abstract]   [Full Text] [Related]  

  • 18. Promising results Halt phase III studies of idelalisib.
    Inman S
    Am J Manag Care; 2014 Feb; 20(2 Spec No.):E9. PubMed ID: 25764575
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
    Smolewski P; Rydygier D
    Expert Opin Pharmacother; 2020 Oct; 21(15):1915-1926. PubMed ID: 32686971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.
    Lopez JP; Jimeno A
    Drugs Today (Barc); 2014 Feb; 50(2):113-20. PubMed ID: 24619588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.